Repligen (NASDAQ:RGEN) Given “Outperform” Rating at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Repligen (NASDAQ:RGEN) in a research note issued to investors on Thursday morning, Benzinga reports. Royal Bank of Canada currently has a $205.00 price objective on the biotechnology company’s stock.

RGEN has been the subject of a number of other reports. Stephens reissued an overweight rating and set a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a buy rating on the stock in a report on Wednesday, July 31st. JPMorgan Chase & Co. increased their target price on Repligen from $190.00 to $200.00 and gave the company an overweight rating in a research report on Wednesday, July 31st. Guggenheim assumed coverage on Repligen in a research report on Tuesday, June 18th. They issued a neutral rating for the company. Finally, Deutsche Bank Aktiengesellschaft raised Repligen from a hold rating to a buy rating and lowered their price objective for the stock from $180.00 to $155.00 in a research report on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $190.25.

Repligen Stock Performance

Shares of RGEN opened at $145.93 on Thursday. The firm has a market capitalization of $8.17 billion, a P/E ratio of 583.74, a PEG ratio of 4.23 and a beta of 0.94. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The business has a fifty day moving average of $148.80 and a 200 day moving average of $153.71. Repligen has a one year low of $110.45 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. During the same period in the previous year, the business earned $0.53 earnings per share. The business’s revenue was down 3.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Repligen will post 1.45 EPS for the current year.

Insider Activity at Repligen

In related news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by company insiders.

Institutional Trading of Repligen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Repligen by 0.4% during the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock worth $937,994,000 after acquiring an additional 21,719 shares during the period. Brown Capital Management LLC lifted its position in Repligen by 5.8% in the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock valued at $274,207,000 after purchasing an additional 83,416 shares during the period. Bank of New York Mellon Corp lifted its position in Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares during the period. Conestoga Capital Advisors LLC increased its holdings in Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after buying an additional 199,322 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in Repligen by 240.5% in the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after buying an additional 425,061 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.